Aromics is an innovative SME, based at the Barcelona Science Park, that works around its technical ability and experience to promote new technologies and products to bring them closer to the market.
"This accreditation is a recognition of our work in R&D for the past 10 years, which has been possible thanks to a young team dedicated to collaborations with companies and research groups in the local and international scene, and also to the support received from the European Commission, the Ministry of Economy and Competitiveness and the Generalitat of Catalonia", Aromics founder and CEO, Carmen Plasencia, says.
As a company with the seal of 'Innovative SME', Aromics will qualify for full compatibility between tax deductions for R&D+i and write offs in social security contributions for research staff working exclusively to these activities. The company will also benefit from ICO Technological Innovation Fund and will be able to participate in public procurements through the so-called Public Procurement of Innovation, in accordance with EU policies in this matter. "This seal is the confirmation of support to companies, like ours, that invest in R&D+i and innovation as a commitment to its growth and sustainability in a very competitive global market", Dr. Plasencia, says.
Aromics specializes in the application of omics sciences (mainly genomics and proteomics) to the research and development of new drugs and diagnostic methods for human health, with the aim of promoting personalized medicine with individualized and more effective treatments. Its strategy focuses on the identification, selection and validation of new molecular markers with the goal of developing new therapies against novel therapeutic targets; designing innovative diagnostic tools for monitoring drug response; and predicting efficiently the efficacy, toxicity and safety of new and/or pre-existing drugs.
"We are currently working on a new anti-tumor agent for the treatment of malignant mesothelioma, a rare tumor, highly aggressive and difficult to treat, related to exposure to asbestos. The candidate compound is currently finalizing the regulatory stage prior to its proof of concept in humans. Now, our goal is to close a small round of funding to carry out the first clinical trial", Aromics CEO, says.
Image: Aromics founder and CEO, Carmen Plasencia (Photo: Daniel Portales, Parc Científic de Barcelona).
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
Research led by IIBB-CSIC and CIBEREHD scientists identifies S-adenosy...
